Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: Five case reports

Clinical Rheumatology

Volumn 18, Issue 4, 1999, Pages 339-345

  Jiang, Hann Kuang ^a   Chang, Deh Ming ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Adverse psychiatric reactions; Non steroidal anti inflammatory drugs; Pain associated syndrome

Indexed keywords

ACECLOFENAC; ALPRAZOLAM; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DICLOFENAC; DIHYDROERGOTAMINE; FENCLOFENAC; FLUOXETINE; GEMFIBROZIL; IBUPROFEN; INDOMETACIN; LITHIUM; LORAZEPAM; MEFENAMIC ACID; NAPROXEN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PROBENECID; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TOLMETIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADULT; ANXIETY NEUROSIS; ARTICLE; DEPRESSION; DRUG SAFETY; FEMALE; HEADACHE AND FACIAL PAIN; HUMAN; MALE; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DISEASE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; VERTIGO;

EID: 0032813662     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100670050114     Document Type: Article

References (33)

1. Brooks PM, May RO. Nonsteroidal anti-inflammatory drugs: differences and similarities. N Engl J Med 1991;324:1716-25.
2. Abramson SB, Weissman G. The mechanisms of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1989;32:1-9.
3. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatr 1994;151:1105-13.
4. Henry DA. Side-effects of non-steroidal anti-inflammatory drugs. Baillières Clin Rheumatol 1988;2:425-54.
5. Browning CH. Nonsteroidal anti-inflammatory drugs and severe psychiatric side-effects. Int J Psychiatr Med 1996;26:25-34.
6. O'Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal anti-inflammatory drugs. J Rheumatol 1985;12:785-90.
7. Clark DW, Ghose K. Neuropsychiatrie reactions to nonsteroidal anti-inflammatory drugs (NSAIDs). The New Zealand experience. Drug Safety 1992;7:460-5.
8. Kruis R, Barger RF. Paranoid psychosis with sulindac. JAMA 1980;243:1420.
9. Thornton TL. Delirium associated with sulindac. JAMA 1980;243:1630-1.
10. Sotsky SM, Tossell JW. Tolmetin induction of mania. Psychosomatics 1984;25:626-8.
11. Griffith JD, Smith CH, Smith RC. Paranoid psychosis in a patient receiving ibuprofen, a prostaglandin synthesis inhibitor: case report. J Clin Psychiatr 1982;43:499-500.
12. Goodwin JS, Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum 1982;25:1013-5.
13. Gotz V. Paranoid psychosis with indomethacin. Br Med J 1978;6104:49.
14. Carney MWP. Paranoid psychosis with indomethacin. Br Med J 1977;6093:994-5.
15. Thompson M, Percy JS. Further experience with indomethacin in the treatment of rheumatic disorders. Br Med J 1966;5479:80-3.
16. Rothermich NO. An extended study of indomethacin. I. Clinical pharmacology. JAMA 1966;195:531-6.
17. Redmond AD. Dyskinesia induced by mefenamic acid? J R Soc Med 1981;74:558-9.
18. Cremona-Barbaro A. Extrapyramidal symptoms following mefenamic acid. J R Soc Med 1983;76:435.
19. Robson RH, Balali M, Critchley J, Proudfoot AT, Prescott L. Mefenamic acid poisoning and epilepsy. Br Med J 1979;6202:1438.
20. Young RJ. Mefenamic acid poisoning and epilepsy. Br Med J 1979;6191:672.
21. Boyle AC. Indomethacin and peptic ulcer. Br Med J 1965;5438:1191.
22. Schwartz JI, Moura RJ. Severe depersonalization and anxiety associated with indomethacin. South Med J 1983;76:679-80.
23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994:103-7.
24. Pinals RS, Runge LA, Jabbs JM, Maddi VI. New nonsteroidal anti-inflammatory drugs: prospective study of relative merits. NY State J Med 1977:77:1268-70.
25. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
26. Taylor D, Lader M. Cytochromes and psychotropic drug interactions. Br J Psychiatr 1996;168:529-32.
27. Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by selective serotonin reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull 1994;30:251-9.
28. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992;13:434-9.
29. Skeith KJ, Hussain MS, Coutts RT, Ramos-Remus C, Avina-Zubieta JA, Russell AS. Adverse drug reactions and debrisoquine/ sparteine (P450IID6) polymorphism in patients with fibromyalgia. Clin Rheumatol 1997;16:291-5.
30. Tonkin AL, Wing LMH. Interactions of non-steroidal antiin-flammatory drugs. Baillières Clin Rheumatol 1988;2:455-83.
31. Ragheb M, Ban TA, Buchanan D, Frolich JC. Interaction of indomethacin and ibuprofen with lithium in manic patients under a steady-state lithium level. J Clin Psychiatr 1980;41:397-8.
32. Brooks PM, Bell MA, Sturrock RD. The clinical significance of indomethacin-probenecid interaction. Br J Clin Pharmacol 1974;1:287-90.
33. Davis A, Day RO, Begg EJ. Interactions between non-steroidal anti-inflammatory drugs and antihypertensives and diuretics. Aust NZ J Med 1986; 16:537-46.